Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Chief Berwick's Appointment May Not Close Door To Near-Term Senate Hearings

This article was originally published in The Pink Sheet Daily

Executive Summary

Republicans on the Senate Finance Committee formally request that the committee hold a hearing with Don Berwick following his recess appointment; Chairman Baucus is receptive to a hearing soon to discuss health reform.

You may also be interested in...



CMS Finally Gets An Administrator; Berwick In Until Late 2011, At Least

Before he has to face a congressional confirmation process, incoming CMS Administrator Donald Berwick will have a year and a half to demonstrate he is, as the Obama administration says, "supremely and uniquely qualified" to implement major health care reforms while overseeing the day-to-day operations of the Centers for Medicare and Medicaid Services

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel